Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 4/2016

01-04-2016 | Neuro

Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma

Authors: Ra Gyoung Yoon, Ho Sung Kim, Dae Yoon Kim, Gil Sun Hong, Sang Joon Kim

Published in: European Radiology | Issue 4/2016

Login to get access

Abstract

Objectives

To determine the diagnostic superiority of parametric response mapping of apparent diffusion coefficient (ADCPR) for predicting glioblastoma treatment response, compared to single time point measurement.

Methods

Fifty post-treatment glioblastoma patients were enrolled. ADCPR was calculated from serial apparent diffusion coefficient (ADC) maps acquired before and at the time of first detection of an enlarged contrast-enhancing lesion on voxel-by-voxel basis. The percentage-decrease in ADCPR and tenth percentile histogram cutoff value of ADC (ADC10) were compared at subsequent 3-month and 1-year follow-ups.

Results

The percentage-decrease in ADCPR was significantly higher in the progression group (mean = 33.2–38.3 %) than in the stable-response group (mean = 9.7 %) at 3 months follow-up (corrected p < 0.001 for both readers). ADCPR significantly improved area under the receiver operating characteristic curve from 0.67 to 0.88 (corrected p = 0.037) and from 0.70 to 0.92 (corrected p = 0.020) for both readers, respectively, compared to ADC10 at 3-month follow-up, but did not significantly improve at 1-year follow-up. The inter-reader agreement was higher for ADCPR than ADC10 (intraclass correlation coefficient, 0.93 versus 0.86).

Conclusion

Voxel-based ADCPR appears to be a superior imaging biomarker than ADC, particularly for predicting early tumour progression in patients with glioblastoma.

Key points

• Treatment response pattern of glioblastoma was evaluated using voxel-based ADCPR and ADC10.
• Voxel-based ADCPR was more accurate in predicting treatment response pattern than ADC10.
• Inter-reader agreement was higher in ADCPR calculation than in ADC10 calculation.
• Voxel-based ADCPR can be a predictor of early treatment response pattern for glioblastoma.
Literature
1.
Kumar AJ, Leeds NE, Fuller GN et al (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217:377–384CrossRefPubMed
2.
Barajas RF Jr, Chang JS, Segal MR et al (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 253:486–496CrossRefPubMedPubMedCentral
3.
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed
4.
Chung WJ, Kim HS, Kim N, Choi CG, Kim SJ (2013) Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging. Radiology 269:561–568CrossRefPubMed
5.
Harry VN, Semple SI, Parkin DE, Gilbert FJ (2010) Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 11:92–102CrossRefPubMed
6.
Oh J, Henry RG, Pirzkall A et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546–554CrossRefPubMed
7.
Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102:5524–5529CrossRefPubMedPubMedCentral
8.
Galban CJ, Chenevert TL, Meyer CR et al (2009) The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 15:572–576CrossRefPubMedPubMedCentral
9.
Hamstra DA, Galban CJ, Meyer CR et al (2008) Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 26:3387–3394CrossRefPubMedPubMedCentral
10.
Chiba Y, Kinoshita M, Okita Y et al (2012) Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma. J Neurosurg 116:835–842CrossRefPubMed
11.
Tsien C, Galban CJ, Chenevert TL et al (2010) Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 28:2293–2299CrossRefPubMedPubMedCentral
12.
Vogelbaum MA, Jost S, Aghi MK et al (2012) Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 70:234–243, discussion 243-234 CrossRefPubMed
13.
Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB (2012) Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med 67:237–245CrossRefPubMed
14.
Moffat BA, Chenevert TL, Lawrence TS et al (2005) Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102:5524–5529CrossRefPubMedPubMedCentral
15.
Sundgren PC, Fan X, Weybright P et al (2006) Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 24:1131–1142CrossRefPubMed
16.
Henry RG, Vigneron DB, Fischbein NJ et al (2000) Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol 21:357–366PubMed
17.
Ellingson BM, Cloughesy TF, Zaw T et al (2012) Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol 14:333–343CrossRefPubMedPubMedCentral
18.
Hamstra DA, Chenevert TL, Moffat BA et al (2005) Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102:16759–16764CrossRefPubMedPubMedCentral
Metadata
Title
Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma
Authors
Ra Gyoung Yoon
Ho Sung Kim
Dae Yoon Kim
Gil Sun Hong
Sang Joon Kim
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 4/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-3896-8

Other articles of this Issue 4/2016

European Radiology 4/2016 Go to the issue

Head and Neck

Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma

Breast

The impact of preoperative axillary ultrasonography in T1 breast tumours

Neuro

Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia

Paediatric

Contrast-enhanced MRI of the knee in children unaffected by clinical arthritis compared to clinically active juvenile idiopathic arthritis patients

Breast

Clinical utility of dual-energy contrast-enhanced spectral mammography for breast microcalcifications without associated mass: a preliminary analysis

Hepatobiliary-Pancreas

Volume-assisted estimation of liver function based on Gd-EOB-DTPA–enhanced MR relaxometry